共 138 条
[1]
Chioncel O(2017)Clinical phenotypes and outcome of patients hospitalized for acute heart failure : the ESC heart failure long-term registry Eur J Heart Fail 19 1242-1254
[2]
Mebazaa A(2022)Trends and complications associated with acute new—onset heart failure : a national readmissions database—based cohort study Heart Fail Rev 27 399-406
[3]
Harjola V(2011)Cardiac gene therapy with SERCA2a: From bench to bedside J Mol Cell Cardiol 50 803-12
[4]
Coats AJ(2002)Pharmacological profile of the novel inotropic agent (E, Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744) J Pharmacol Exp Ther 303 592-600
[5]
Piepoli MF(2005)Modulation of sarcoplasmic reticulum function by Na+/K + pump inhibitors with different toxicity: digoxin and PST2744 [(E, Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride] J Pharmacol Exp Ther 313 207-215
[6]
Crespo-leiro MG(2008)Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent. A randomized controlled trial in patients hospitalized with heart failure J Am Coll Cardiol 51 2276-85
[7]
Mir T(2009)Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in P Am Heart J 157 1035-1041
[8]
Uddin M(2007)Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure Am J Cardiol 99 41A-46A
[9]
Qureshi WT(2023)Istaroxime metabolite PST3093 selectively stimulates SERCA2a and reverses disease-induced changes in cardiac functions J Pharmacol Exp Ther 384 231-244
[10]
Shanah L(2020)Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial Eur J Heart Fail 22 1684-1693